Matrix Metalloproteinase 7, Pro, Recombinant (ProMMP-7, Promatrilysin)

Matrix metalloproteinase-7 (MMP-7) also known as matrilysin and PUMP (EC 3.4.24.23) cleaves a number of substrates including collagen types IV and X, elastin, fibronectin, gelatin, laminin and proteoglycans. MMP-7 is closely related to the stromelysin family members but is encoded by a different gene. MMP-7 is the smallest of all the MMPs consisting of a pro-peptide domain and a catalytic domain. It lacks the hemopexin-like domain common to other members of the MMPs. MMP-7 is secreted as a 28kD proenzyme and can be activated in vitro by organomercurials and trypsin and in vivo by MMP-3 to a 18kD active MMP-7 enzyme. Once activated, MMP-7 can activate pro-MMP-1 and pro-MMP-9 but not pro-MMP-2. MMP-7 is widely expressed having been reported in elevated levels in cycling endometrium as well as in colorectal cancers and adenomas, hepatocellular carcinomas, rectal carcinomas, and approximately 50% of gliomas.\n\nDimers and Aggregates:\n(same/less than) 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nBiological Activity:\nThe specific activity was found to be ~1400IU/mg.\n\nUnit Definition:\nOne unit is defined as the digestion of 1ug Azocoll/min at 37 degrees C.\n\nEndotoxin:\n(same/less than) 0.1ng/ug (IEU/ug) of Recombinant ProMMP-7\n\nStorage and Stability:\nMay be stored at 4 degrees C for short-term only. For long-term storage, store at -20 degrees C. Aliquots are stable for at least 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

M2423-12

Size

5ug

Form

Supplied as a liquid in 25mM Tris-HCl, pH 7.5, 150mM sodium chloride, 5mM calcium chloride, 0.01% Brij-35, 0.02% sodium azide.

Purity

(same/more than) 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.

References

1. Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression. Udayakumar TS, Bair EL, Bowden GT, Mol Carcinog 2003 Oct;38(2):70-7 2. Androgens block interleukin-1 beta-induced promatrilysin expression in prostate carcinoma cells. Stratton MS, Greenstein B, Nagle RB, Prostate 2002 Sep 15;53(1):1-8 3. Fibroblast growth factor-1 induced promatrilysin expression through the activation of extracellular-regulated kinases and STAT3. Udayakumar TS, Stratton MS, Bowden GT, Neoplasia 2002 Jan-Feb;4(1):60-7 4. Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP. Maliner-Stratton MS, Klein RD, Nagle RB, Neoplasia 2001 Nov-Dec;3(6):509-20 5. Expression of the matrix metalloproteinase promatrilysin in coculture of prostate carcinoma cell lines. Stratton MS, Sirvent H, Nagle RB, Prostate 2001 Aug 1;48(3):206-9 6. Aberrant expression of fibroblast growth factor receptor-1 in prostate epithelial cells allows induction of promatrilysin expression by fibroblast growth factors. Udayakumar TS, Klein RD, Nagle RB, Int J Cancer 2001 Jan 15;91(2):187-92.